TuesdaySep 01, 2020 1:26 pm

PsychedelicNewsBreaks — Cybin Corp. Names Health-Care, M&A Expert as New Chief Executive Officer

Cybin Corp., a life-sciences company advancing psychedelic pharmaceuticals, has announced that Doug Drysdale has been appointed as CEO. With more than three decades of experience, Drysdale brings invaluable insight and expertise to his new role. In 2014 as a corporate director of a NASDAQ-listed pharmaceutical company, he led the company’s recapitalization efforts, raising an estimated $65 million. Consequently, he was appointment chairman and CEO and revamped the company’s management team and board of directors while also building a 220-person sales team — all within the first year. Ultimately he grew the company’s enterprise value exponentially from $80 million to around…

Continue Reading

ThursdayAug 27, 2020 2:36 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) to Offer Esketamine for Treatment of Adults with MDD at Flagship Clinic

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced that it is expanding its rapid-onset treatment service for major depressive disorder (“MDD”). According to the update, Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic, the Canadian Rapid Treatment Centre of Excellence (“CRTCE”), starting in September 2020. Declared a breakthrough treatment for depression by the US Food and Drug Administration (“FDA”), esketamine was approved by Health Canada for the treatment of MDD in May 2020. “The availability of esketamine at the CRTCE provides tremendous opportunity for adults across Canada affected by treatment-resistant depression…

Continue Reading

WednesdayAug 26, 2020 2:48 pm

PsychedelicNewsBreaks – Cybin Corp. Poised Amid Groundbreaking Decision to Allow Psilocybin Therapy

Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU), and this groundbreaking decision bodes well for companies such as Cybin, which are operating in the sector. The approval marks the first known, legal medical exemption for psilocybin use in Canada since the compound became illegal in the country in 1974. A recent article discussing this anticipates more applications through the exemption…

Continue Reading

FridayAug 21, 2020 1:43 pm

PsychedelicNewsBreaks – Pure Extracts Corp. Holds Clear Advantage in Space Where Purity, Quality Are Equal

Pure Extracts, a private, plant-based extraction company, stands out to meet demand in the psychedelic and functional mushroom industries, which are among North America’s fastest-growing segments.  While few can deliver to this emerging space that requires extraction for product development, Pure Extracts leverages substantial experience and technical competence, creating a distinct advantage as it focuses on partnering with companies developing powerful mushroom products. A recent article discussing this reads, “With its proven expertise and EU Good Manufacturing Practices (“GMP”) designed facility for licensed extraction, Pure Extracts offers a clear competitive advantage. In a space where product purity is equal to…

Continue Reading

WednesdayAug 19, 2020 2:03 pm

PsychedelicNewsBreaks – Cybin Corp. Partners with IntelGenx to Develop Efficient Delivery Method for Pharmaceutical-Grade Psilocybin

Cybin Corp. recently announced its entry into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://ibn.fm/TZeVy). Under the agreement, the two companies will collaborate to develop an orally dissolving, fast-acting film for the delivery of pharmaceutical-grade psilocybin. A recent article discussing this quotes Cybin’s Chief Medical Officer Dr. Jukka Karjalainen, who states, “We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film. Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic…

Continue Reading

FridayAug 07, 2020 5:58 pm

PsychedelicNewsBreaks — Cybin Calls Approval for Psilocybin Therapy in Palliative Care Treatment a ‘Watershed Moment’

Cybin Corp., Canada's leading-edge mushroom life-sciences company, has noted its strong support for TheraPsil, a nonprofit coalition that advocates for legal, Special Access Programme ("SAP") access to psilocybin therapy for palliative care of Canadians. The coalition recently announced that Federal Minister of Health Patty Hajdu has approved the use psilocybin therapy in the end-of-life care for four Canadians diagnosed with incurable cancer. The four are the first publicly known individuals to legally use psilocybin since the compound became illegal in Canada in 1974. “This is a watershed moment for the patients involved who deserve the right to manage their health…

Continue Reading

WednesdayAug 05, 2020 11:24 am

PsychedelicNewsBreaks – Cybin Corp. Positioned in Shifting Trend Toward Psilocybin

Cybin Corp., Canada's premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products, looks to be at the right place at the right time during a shifting trend toward psilocybin. Highlighting this shift, TheraPsil, a non-profit coalition that advocates for legal, compassionate access to psilocybin therapy for palliative Canadians, recently shared news that four palliative Canadians were approved for end-of-life psilocybin therapy. This approval, through section 56(1), represents the first legal medical exemptions for psilocybin in Canada since the 1970s. “I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgement…

Continue Reading

TuesdayAug 04, 2020 12:39 pm

PsychedelicNewsBreaks – Pure Extracts Corp. to Drive Product Innovation with Leading-Edge Team, Technology

Pure Extracts, a private, plant-based extraction company with a new vertical in functional mushrooms, leverages a team of qualified experts and cutting-edge technology. The company’s distinction on a path toward opportunity was highlighted in a recent article, which reads, “Pure Extracts, on the other hand, is ideally positioned to enter the space as an experienced producer. With a team of qualified experts and cutting-edge extraction technology, the company is set up for long-term strategic distribution and product innovation. Located near Whistler, British Columbia, the company’s facility is built for EU-GMP certification, which allows for international sales and ensures the production…

Continue Reading

WednesdayJul 29, 2020 2:06 pm

PsychedelicNewsBreaks – Cybin Corp. to Deliver Psychedelic Medicines Targeting Conditions Failed by Big Pharma

Cybin Corp. appears set for opportunity as new data increasingly finds promise in psychedelic medicines. As big pharma has failed to bring groundbreaking drug innovations into the mental-health space, psilocybin — the main compound of pharmaceutical psychedelic products — stands out, having shown positive results for the treatment of anxiety, depression, addiction, and eating and other disorders. A recent article discussing the company’s positioning reads, “Cybin is potentially poised to be the first company to develop psilocybin-based medicine designed to target major depressive disorders. Currently involved in structuring a clinical study that will be conducted through an academic partner in…

Continue Reading

MondayJul 27, 2020 9:38 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Files Acquisition Reports, Appoints New Director

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), on Friday announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. The filings are part of Champignon’s commitment to work with the British Columbia Securities Commission to complete its previously announced disclosure review. The Company also announced its appointment of Dr. Roger McIntyre, Champignon CEO, to its Board of Directors. Dr. McIntyre’s appointment will replace Pat McCutcheon’s position as a director of the Company. To view the full press release, visit http://ibn.fm/RDypi About Champignon Brands Inc.…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050